Pharmaceutical Executive Daily: FDA Approves Pimjetmi

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, FDA approves Merck KGaA’s Pimjetmi as an oral option for symptomatic tenosynovial giant cell tumor, Parexel chief patient officer Stacy Hurt argues patient input belongs in clinical trials from the earliest phases, and Ignite Proteomics’ Dr. Brian Corgiat on why treatment decisions must account for how tumors mutate over time.

FDA approved Merck KGaA’s Pimjetmi, a once-daily oral CSF-1R inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor who are poor surgical candidates. In the Phase III Maneuver trial, Pimjetmi achieved an objective response rate of 56% versus 3% for placebo at week 25, with an early onset of response and no evidence of cholestatic hepatotoxicity.

Parexel chief patient officer Stacy Hurt argues that patient input should be gathered from the earliest stages of clinical research, pushing back against sponsors who view early-phase feedback as premature. She notes that a single Phase III amendment costs an average of $535,000, making early patient input a cost-effective way to mitigate risk and avoid later protocol changes.

Finally, Ignite Proteomics senior clinical research scientist Dr. Brian Corgiat explains why tumors, as living cells under therapeutic pressure, shift over time as resistance mechanisms emerge, often leaving recurrent tumors meaningfully different from their original form. He contends that targeting a tumor based on outdated mutation data risks ineffective treatment, and makes the case for phosphoproteome testing to capture which proteins are actively driving a tumor at the moment of biopsy.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.